10/02/23 6:50 AMNasdaq : ANIP fda approvallow floatANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis FlaresCortrophin Gel is the only FDA-approved purified corticotropin (ACTH) indicated for the treatment of appropriate patients with acute gouty arthritis flares New 1-mL size furthers ANI’s commitment to providing ACTH options for appropriate acute gouty arthritis flare patients and their healthcareRHEA-AIneutral
09/18/23 4:05 PMNasdaq : ANIP conferenceslow floatANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Global Healthcare Conference 2023 in New York CityRHEA-AIneutral
09/12/23 6:50 AMNasdaq : ANIP fda approvallow floatANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USPANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Tablets USP. ANI’s Estradiol TabletsRHEA-AIneutral
08/28/23 6:50 AMNasdaq : ANIP fda approvallow floatANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.1%. ANI’s Estradiol Gel, 0.1%, isRHEA-AIneutral
08/24/23 6:50 AMNasdaq : ANIP conferenceslow floatANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 25 th Annual Global Investment ConferenceRHEA-AIneutral
08/23/23 6:50 AMNasdaq : ANIP managementlow floatANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of DirectorsANIRHEA-AIneutral
08/09/23 6:50 AMNasdaq : ANIP earningslow floatANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Record quarterly adjusted non-GAAP EBITDA of $34.1RHEA-AIneutral
07/31/23 7:17 AMNasdaq : ANIP earningslow floatANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ETANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 financial results on Wednesday, August 9, 2023, prior to the market open. Nikhil Lalwani, President and ChiefRHEA-AIneutral
05/22/23 4:05 PMNasdaq : ANIP, ANI conferenceslow floatANI Pharmaceuticals to Present at the Jefferies Healthcare ConferenceANI Pharmaceuticals, Inc. today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Healthcare Conference in New York City as follows:. The live and archived webcast of the presentation will be accessible from the Company’ s website at www.anipharmaceuticals.com, under the...RHEA-AIneutral
05/16/23 4:05 PMNasdaq : ANIP offeringlow floatANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional SharesA total of 2,183,545 shares of its common stock were sold at a public offering price of $39.50 per share, inclusive of the exercise in full of the underwriters’ option to purchase an additional 284,810 shares of common stock. The gross proceeds of the offering to the Company are approximately $86.25 million, before deducting the underwriting discounts and...RHEA-AIneutral